postmarketing surveillance For Investigating success in achieving clinical and functional Remission and Sustaining efficacy with Tocilizumab in BIOlogics naive RA patients
Not Applicable
- Conditions
- Patients with rheumatoid arthritis who have been diagnosed based on the 2010 ACR/EULAR new classification criteria for RA Patients who have no previous medical history of biological agents for RA Patients whose disease activity is DAS28>=3.2 at baseline
- Registration Number
- JPRN-UMIN000006914
- Lead Sponsor
- Chugai Pharmaceutical Co. Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
Not provided
Exclusion Criteria
No criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients achieving remission by the new ACR/EULAR Boolean based criteria at week 52. (Comparing the remission rate by disease duration)
- Secondary Outcome Measures
Name Time Method Adverse reaction incidence